A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer

Withdrawn before enrolling · Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.

Key facts

Study ID

NCT01184287

Run by

Tamir Biotechnology, Inc.

People needed

0

Last updated by the study team

2015-09-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than 18 years
• ECOG less than 2
• Estimated survival of greater than 12 weeks

You may not qualify if…

• Prior systemic chemotherapy for locally advanced or metastatic NSCLC
• Use of any investigational agent within 28 days prior to registration
• Known hypersensitivity to any of the study drugs
• Brain metastases or leptomeningeal disease
• History of prior malignancy within the past three years

Where it is running

• Tower Cancer Research Foundation — Beverly Hills, California, United States
• Van Andel Research Institute — Grand Rapids, Michigan, United States
• Sletten Cancer Specialists — Great Falls, Montana, United States
• The Cancer Institute at NYU Langone Medical Center — New York, New York, United States
• Tri-county Hematology-Oncology Associates, Inc — Canton, Ohio, United States
• Northern Utah Associates — Ogden, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.